Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 8:11 p.m.

    📋 Virios Therapeutics Inc. (VIRI) - Clinical Trial Update

    Filing Date: 2026-01-13

    Accepted: 2026-01-13 12:38:14

    Event Type: Clinical Trial Update

    Event Details:

    Virios Therapeutics Inc. (VIRI) Announces Clinical Trial Update Virios Therapeutics Inc. (VIRI) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: investor
    • Diseases/Conditions: up to approximately $12
    • Collaboration: GLOBE NEWSWIRE
    • Updated Timeline: January 12, 2025

    🔬 Clinical Development Pipeline (Virios Therapeutics Inc.):

    Product Type Development Stage Therapeutic Area Source
    Serine proteinase-1 (Serp-1) DRUG Phase PHASE2 Unstable Angina ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Non-alcoholic Fatty Liver Disease ClinicalTrials.gov
    MSDC-0602K DRUG Phase PHASE2 Non-alcoholic Fatty Liver Disease ClinicalTrials.gov
    Laromustine (VNP40101M) and Ara-C DRUG Phase PHASE1 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Placebo BID Tablet DRUG Phase PHASE2 Fibromyalgia ClinicalTrials.gov
    IMC-1 DRUG Phase PHASE2 Fibromyalgia ClinicalTrials.gov
    Carotuximab DRUG Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    Osimertinib DRUG Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Virios Therapeutics Inc.
    • Ticker Symbol: VIRI

Search

News categories